the Mirati drug, called adagrasib, shrank tumors in 43% of patients with advanced lung cancer
With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment
s Mirati Therapeutics waits for the Food and Drug Administration to complete a review of its KRAS-targeting lung cancer drug later this year, final results from a clinical trial reported...
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35329953/
Given the limitations due to the small sample size and exploratory nature of this study, we tentatively conclude the KRAS G12C mutation should be considered in future trials as a...
Conclusions: Given the limitations due to the small sample size and exploratory nature of this study, we tentatively conclude the KRAS G12C mutation should be considered in future trials as a predictive marker of prolonged response to first-line ICIs in NSCLC patients overexpressing PD-L1. This finding could be relevant as anti-KRAS G12C...
KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333412/
doi: 10.1002/jso.26860. Online ahead of print. 1 Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Background: Next-generation sequencing (NGS) provides information on...
Conclusion: This study demonstrates the importance of KRAS mutant allele frequency on pathological characteristics and prognosis in right-sided PDAC treated with surgery.
Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35302596/
doi: 10.1158/1078-0432.CCR-21-3581. Online ahead of print. 1 Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, mi, United States. 2 Karmanos Cancer Institute, Detroit, United States. 3 Caris Life...
Conclusions: KRAS-WT PDAC represents 10.7% of PDAC and is enriched with targetable alterations, including immuno-oncologic markers. Identification of KRAS-WT patients in clinical practice may expand therapeutic options in a clinically meaningful manner.
KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35303157/
Analysis of ctDNA is a viable strategy for clinical management of mCRC patients. Although the OncoBEAM assay sensitivity is somewhat higher, the fully automated Idylla platform also has good performance,...
Conclusions: Analysis of ctDNA is a viable strategy for clinical management of mCRC patients. Although the OncoBEAM assay sensitivity is somewhat higher, the fully automated Idylla platform also has good performance, while being cheaper and much less labor-intensive, for the detection of RAS mutations in plasma, either at diagnosis or after...